These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6178461)

  • 41. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration.
    Gill M; Murday V; Slack J
    Soc Sci Med; 1987; 24(9):725-31. PubMed ID: 2440113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of pregnancy outcome after amniocentesis for previous neural tube defect or raised maternal serum alphafetoprotein.
    Read AP; Donnai D; Harris R; Donnai P
    Br J Obstet Gynaecol; 1980 May; 87(5):372-6. PubMed ID: 6155932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maternal serum alpha-fetoprotein screening for the early antenatal detection of neural tube defects.
    Ward AM
    Ric Clin Lab; 1982; 12(1):189-93. PubMed ID: 6178141
    [No Abstract]   [Full Text] [Related]  

  • 44. Down's syndrome: current screening techniques.
    White RS
    South Med J; 1989 Dec; 82(12):1483-6. PubMed ID: 2480649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A survey of diagnostic amniocenteses in Oxford from 1974-1981.
    Terzian E; Boreham J; Cuckle HS; Wald NJ; Bobrow M; Lindenbaum R; Turnbull AC
    Prenat Diagn; 1985; 5(6):401-14. PubMed ID: 2418435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
    Piggott M; Wilkinson P; Bennett J
    J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. alpha-Fetoprotein screening.
    Burton BK
    Adv Pediatr; 1986; 33():181-96. PubMed ID: 2432763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prenatal testing for maternal serum alpha-fetoprotein.
    Schwager EJ; Weiss BD
    Am Fam Physician; 1987 Apr; 35(4):169-74. PubMed ID: 2436465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. New England Regional Genetics Group Prenatal Collaborative Study of Down Syndrome Screening.
    Am J Obstet Gynecol; 1989 Mar; 160(3):575-81. PubMed ID: 2467563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prenatal serum alpha-fetoprotein screening for neural tube defects.
    Macri JN; Weiss RR
    Obstet Gynecol; 1982 May; 59(5):633-9. PubMed ID: 6175932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should amniocenteses always accompany unexplained high maternal serum alpha-fetoprotein levels? Who decides: public agency, patient, or private physician?
    Stephens JD
    Am J Obstet Gynecol; 1990 Aug; 163(2):697-8. PubMed ID: 1696782
    [No Abstract]   [Full Text] [Related]  

  • 52. Four years' experience of maternal alpha-fetoprotein screening and its effect on the pattern of antenatal care.
    Ward RH; Fairweather DV; Whyley GA; Shirley IM; Lucas M
    Prenat Diagn; 1981 Apr; 1(2):91-101. PubMed ID: 6180424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Midtrimester screening for open neural tube defects: correlation of sonography with amniocentesis results.
    Lindfors KK; McGahan JP; Tennant FP; Hanson FW; Walter JP
    AJR Am J Roentgenol; 1987 Jul; 149(1):141-5. PubMed ID: 2438918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal serum alpha-fetoprotein screening, maternal weight, and detection efficiency.
    Macri JN; Kasturi RV; Krantz DA; Koch KE
    Am J Obstet Gynecol; 1986 Oct; 155(4):758-60. PubMed ID: 2429547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maternal serum alpha fetoprotein testing: some public policy considerations.
    Kasper AS
    Women Health; 1981; 6(1-2):147-53. PubMed ID: 11650640
    [No Abstract]   [Full Text] [Related]  

  • 56. Maternal serum alpha-fetoprotein screening: promise not yet fulfilled.
    Nadler HL; Simpson JL
    Am J Obstet Gynecol; 1979 Sep; 135(1):1-2. PubMed ID: 89812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Study on key techniques and intervention in reducing birth defects].
    Zhu BS; Su J; Lu XH; He J; Zhu S; Jiao CX; Zhang JM; Tang XH; Tao Y; Lin KP; Chen H; Li SY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Sep; 46(9):658-63. PubMed ID: 22176989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maternal serum alpha-fetoprotein and fetal trisomy-21 in women 35 years and older: implications for alpha-fetoprotein screening programs.
    Ashwood ER; Cheng E; Luthy DA
    Am J Med Genet; 1987 Mar; 26(3):531-9. PubMed ID: 2436476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parent preferences and prenatal testing for neural tube defects.
    Ennever FK; Lave LB
    Epidemiology; 1995 Jan; 6(1):8-16. PubMed ID: 7534119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prenatal fetal karyotyping and maternal serum alpha-fetoprotein screening.
    Gosden C; Buckton K; Fotheringham Z; Brock DJ
    Br Med J (Clin Res Ed); 1981 Jan; 282(6260):255-8. PubMed ID: 6161673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.